Nektar Therapeutics [NKTR] stock is trading at $0.64, up 4.88%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The NKTR shares have gain 27.51% over the last week, with a monthly amount drifted -29.07%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Nektar Therapeutics [NASDAQ: NKTR] stock has seen the most recent analyst activity on April 11, 2025, when Jefferies upgraded its rating to a Buy but kept the price target unchanged to $2 for it. Previously, Oppenheimer upgraded its rating to Outperform on March 14, 2025, and kept the price target unchanged to $6. On January 08, 2025, B. Riley Securities initiated with a Buy rating and assigned a price target of $4 on the stock. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $6.50 on December 10, 2024. Piper Sandler initiated its recommendation with a Overweight and recommended $7 as its price target on November 04, 2024. In a note dated June 28, 2024, Rodman & Renshaw initiated an Buy rating and provided a target price of $2 on this stock.
Nektar Therapeutics [NKTR] stock has fluctuated between $0.43 and $1.93 over the past year. Currently, Wall Street analysts expect the stock to reach $16.75 within the next 12 months. Nektar Therapeutics [NASDAQ: NKTR] shares were valued at $0.64 at the most recent close of the market. An investor can expect a potential return of 2517.19% based on the average NKTR price forecast.
Analyzing the NKTR fundamentals
Nektar Therapeutics [NASDAQ:NKTR] reported sales of 98.43M for the trailing twelve months, which represents a growth of 22.15%. Gross Profit Margin for this corporation currently stands at 0.69% with Operating Profit Margin at -0.92%, Pretax Profit Margin comes in at -1.21%, and Net Profit Margin reading is -1.21%. To continue investigating profitability, this company’s Return on Assets is posted at -0.39, Equity is -1.51 and Total Capital is -0.38. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.69.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.6053 points at the first support level, and at 0.5742 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.6622, and for the 2nd resistance point, it is at 0.6880.
Ratios To Look Out For
For context, Nektar Therapeutics’s Current Ratio is 4.26. Further, the Quick Ratio stands at 4.26, while the Cash Ratio is 0.72. Considering the valuation of this stock, the price to sales ratio is 1.20, the price to book ratio is 1.95.
Transactions by insiders
Recent insider trading involved Zalevsky Jonathan, Chief R&D Officer, that happened on Feb 19 ’25 when 10300.0 shares were sold. Chief Legal Officer, Wilson Mark Andrew completed a deal on Feb 19 ’25 to sell 11040.0 shares. Meanwhile, President & CEO ROBIN HOWARD W sold 23774.0 shares on Feb 19 ’25.
